| __timestamp | AstraZeneca PLC | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 51796000 |
| Thursday, January 1, 2015 | 5997000000 | 72758000 |
| Friday, January 1, 2016 | 5890000000 | 61008000 |
| Sunday, January 1, 2017 | 5757000000 | 66962000 |
| Monday, January 1, 2018 | 5932000000 | 84888000 |
| Tuesday, January 1, 2019 | 5958000000 | 107068000 |
| Wednesday, January 1, 2020 | 5991000000 | 122964000 |
| Friday, January 1, 2021 | 9736000000 | 208808000 |
| Saturday, January 1, 2022 | 9762000000 | 253297000 |
| Sunday, January 1, 2023 | 10935000000 | 216566000 |
| Monday, January 1, 2024 | 13583000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, AstraZeneca PLC and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, AstraZeneca's R&D expenses surged by approximately 96%, peaking in 2023. This reflects their commitment to expanding their drug pipeline and maintaining a competitive edge. In contrast, BioCryst Pharmaceuticals, while significantly smaller, increased their R&D spending by over 300% during the same period, highlighting their aggressive push towards niche therapeutic areas. Notably, AstraZeneca's R&D budget in 2023 was nearly 50 times that of BioCryst, underscoring the scale difference between the two companies. These trends not only reveal strategic priorities but also hint at future market dynamics in the pharmaceutical sector.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Zoetis Inc.
AstraZeneca PLC vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Iovance Biotherapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Amphastar Pharmaceuticals, Inc.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.